Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Operating Leases (2019 - 2025)

Theravance Biopharma (TBPH) has disclosed Operating Leases for 7 consecutive years, with $33.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Leases fell 17.42% to $33.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $33.7 million, a 17.42% decrease, with the full-year FY2024 number at $39.1 million, changed N/A from a year prior.
  • Operating Leases was $33.7 million for Q3 2025 at Theravance Biopharma, down from $35.6 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $57.8 million in Q2 2021 to a low of $33.7 million in Q3 2025.
  • A 5-year average of $45.0 million and a median of $43.8 million in 2023 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: rose 21.28% in 2021, then fell 19.97% in 2023.
  • Theravance Biopharma's Operating Leases stood at $54.4 million in 2021, then fell by 16.46% to $45.4 million in 2022, then fell by 9.45% to $41.1 million in 2023, then dropped by 4.89% to $39.1 million in 2024, then dropped by 13.88% to $33.7 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Operating Leases are $33.7 million (Q3 2025), $35.6 million (Q2 2025), and $37.3 million (Q1 2025).